Abstract
Purpose
The purpose of this review is to update the MASCC (Multinational Association of Supportive Care in Cancer) guidelines for controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Methods
The antiemetic study group of MASCC met in Copenhagen in 2015 to review the MASCC antiemetic guidelines. A subgroup performed a systematic literature review on antiemetics for low emetogenic chemotherapy (LEC) and chemotherapy of minimal emetic potential and the chair presented the update recommendation to the whole group for discussion. They then voted with an aim of achieving 67 % or greater consensus.
Results
For patients receiving low emetogenic chemotherapy, a single antiemetic such as dexamethasone, a 5HT3 receptor antagonist, or a dopamine receptor antagonist may be considered for prophylaxis of acute emesis. For patients receiving chemotherapy of minimal emetogenicity, no antiemetic should be routinely administered. If patients vomit, they should be treated as for chemotherapy of low emetic potential. No antiemetic should be administered for prevention of delayed nausea and vomiting induced by low or minimally emetogenic chemotherapy.
Conclusions
More research is needed to determine the incidence of emesis, particularly delayed emesis, in the LEC group. Prospective studies are required to evaluate antiemetic strategies. The risk of emesis within LEC may be more accurately determined by adding the patient risk factors for emesis to those of the chemotherapy drugs. Improved strategies for promoting adherence to guidelines are required.
Similar content being viewed by others
References
Hesketh PJ, Kris KG, Grunberg SM, et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109
Grunberg SM, Osaba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic emetogenicity—an update. Support Care Cancer 13:80–84
http://www.mascc.org/antiemetic-guidelines Last accessed 27th Feb 2016
Perry CM, Wiseman LR (1999) Trastuzumab. BioDrugs 12(2):129–135
Al-Dasooqi N, Boen JM, Gibson RJ, et al. (2009) Trastuzumab induces gastrointestinal side effects in HER2-overexpresssing breast cancer patients. Investig New Drugs 27:173–178
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf Last accessed 27th February 2016
Robert C, Schachter J, Long GV, et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med 372:2521–2532
Einhorn LH, Brames MJ (2006) Emetic potential of daily oral etoposide. Support Care Cancer 14:1262–1265
Tonato M, Clark-Snow RA, Osoba D, et al. (2005) Emesis induced by low or minimal emetogenic risk chemotherapy. Support Care Cancer 13:109–111
Basch E, Hesketh PJ, Kris MJ, et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Practice 7:395–398
https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Last accessed 17th Feb 2016
Vardy J, Chiew KS, Galica J, et al. (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015
Italian group for antiemetic research (2004) Randomised double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:752–729
Costa AL, Abreu C, Pacheo TR et al (2015) Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumours. Biomed Res Int. Article ID 309601. doi: 10.1155/2015/309601
Hayashi T, Ikesue H, Esaki T, et al. (2010) Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation. Support Care Cancer 20:1805–1810
Keat CH, Phua G, Kassim MSA, et al. (2013) Can granisetron injection used as a primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy? Asia Pacific J Cancer Prev 14:469–473
Fabi A, Barduagni M, Lauro S, et al. (2011) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156–161
Molassiotis A, Saunders MP, Valle J, et al. (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201–208
Gralla R, Lichinitser M, Van Der Vegt S, et al. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577
Saito M, Aogi K, Sekine I, et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124
Aapro MS, Grunberg SM, Manikhas GM, et al. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449
Schwartzberg L, Morrow G, Balu S, et al. (2011) Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Curr Med Res Opin 27:1613–1622
Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D (2012) Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Support Care Cancer 20:2633–2637
Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomised phase II trial. J Support Oncol 9:188–195
Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1091–1090
Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19:807–813
D’Acqusito RW, Tyson LB, Gralla RJ, et al. (1986) The influence of chromic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257
Morrow GR (1985) The effect of susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55:2766–2770
Olver IN, Taylor AE, Whitford H (2005) Relationships between patients’ pre-treatment expectations of toxicities and post chemotherapy experiences. Psycho-Oncology 14:25–33
Aapro M, Molassiotis A, Dicato M, et al. (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992
Yu S, Burke TA, Chan A, et al. (2014) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 23:273–282
Olver I, von Dincklage J, Nicholson J, Shaw T (2016) Improving uptake of wiki-based guidelines with Qstream education. Med Educ 50:590–591
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors received remuneration, research funding, and consultancies as follows:
I Olver: Tesaro; C Ruhlmann: Swedish Orphan Biovitrum; F Jahn: MSD, Merck, Helsinn, Tesaro; L Schwartzberg: Eisai, Merck, Helsinn, Tesaro; B Rapoport: Merck, Helsinn, MSD Tesaro; C Rittenberg: none; R Clark-Snow: none.
Rights and permissions
About this article
Cite this article
Olver, I., Ruhlmann, C.H., Jahn, F. et al. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer 25, 297–301 (2017). https://doi.org/10.1007/s00520-016-3391-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-016-3391-z